Last 12 months
Inside the activity.
6 purchase rows · 11 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 1 | 0 |
| Feb 2026 | 2 | 0 |
| Mar 2026 | 0 | 6 |
| Apr 2026 | 2 | 0 |
| May 2026 | 1 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 3 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 24, 2020 Filed Apr 28, 2020 21:20 UTC |
Alpern Robert JDirector
|
GrantCommon shares without par value | 1,974 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-005178 · edgar.xml · nonDerivative · entry 1 Alpern Robert J · CIK 0001448074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,380 F1 · shares: These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| April 24, 2020 Filed Apr 28, 2020 21:21 UTC |
AUSTIN ROXANNE SDirector
|
GrantOption (right to buy) · Derivative | 9,735 | $0.00 Strike: $93.68 | $0.00 |
DisclosureSEC source: 0001179110-20-005179 · edgar.xml · derivative · entry 2 AUSTIN ROXANNE S · CIK 0001061632 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,735 Underlying: Common shares · 9,735 shares Expires 2030-04-23 F2 · security: Stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| April 24, 2020 Filed Apr 28, 2020 21:21 UTC |
AUSTIN ROXANNE SDirector
|
GrantCommon shares without par value | 1,974 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-005179 · edgar.xml · nonDerivative · entry 1 AUSTIN ROXANNE S · CIK 0001061632 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,887 F1 · shares: These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| April 24, 2020 Filed Apr 28, 2020 21:22 UTC |
Blount Sally E.Director
|
GrantCommon shares without par value | 1,974 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-005180 · edgar.xml · nonDerivative · entry 1 Blount Sally E. · CIK 0001537286 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,240 F1 · shares: These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| April 24, 2020 Filed Apr 28, 2020 21:22 UTC |
Kumbier MichelleDirector
|
GrantCommon shares without par value | 1,974 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-005181 · edgar.xml · nonDerivative · entry 1 Kumbier Michelle · CIK 0001640036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,248 F1 · shares: These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). F2 · balance_after: Balance includes shares acquired pursuant to a dividend reinvestment feature. Read SEC document |
| April 24, 2020 Filed Apr 28, 2020 21:23 UTC |
LIDDY EDWARD MDirector
|
GrantOption (right to buy) · Derivative | 9,671 | $0.00 Strike: $93.68 | $0.00 |
DisclosureSEC source: 0001179110-20-005182 · edgar.xml · derivative · entry 2 LIDDY EDWARD M · CIK 0001188983 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,671 Underlying: Common shares · 9,671 shares Expires 2030-04-23 F2 · security: Stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| April 24, 2020 Filed Apr 28, 2020 21:23 UTC |
LIDDY EDWARD MDirector
|
GrantCommon shares without par value | 1,974 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-005182 · edgar.xml · nonDerivative · entry 1 LIDDY EDWARD M · CIK 0001188983 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,127 F1 · shares: These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| April 24, 2020 Filed Apr 28, 2020 21:23 UTC |
McDew Darren WDirector
|
GrantCommon shares without par value | 1,974 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-005183 · edgar.xml · nonDerivative · entry 1 McDew Darren W · CIK 0001787479 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,974 F1 · shares: These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| April 24, 2020 Filed Apr 28, 2020 21:24 UTC |
McKinstry NancyDirector
|
GrantOption (right to buy) · Derivative | 8,454 | $0.00 Strike: $93.68 | $0.00 |
DisclosureSEC source: 0001179110-20-005185 · edgar.xml · derivative · entry 2 McKinstry Nancy · CIK 0001294731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,454 Underlying: Common shares · 8,454 shares Expires 2030-04-23 F2 · security: Stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| April 24, 2020 Filed Apr 28, 2020 21:24 UTC |
McKinstry NancyDirector
|
GrantCommon shares without par value | 1,974 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-005185 · edgar.xml · nonDerivative · entry 1 McKinstry Nancy · CIK 0001294731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,640 F1 · shares: These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| April 24, 2020 Filed Apr 28, 2020 21:25 UTC |
NOVAKOVIC PHEBE NDirector
|
GrantOption (right to buy) · Derivative | 9,030 | $0.00 Strike: $93.68 | $0.00 |
DisclosureSEC source: 0001179110-20-005186 · edgar.xml · derivative · entry 2 NOVAKOVIC PHEBE N · CIK 0001222195 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,030 Underlying: Common shares · 9,030 shares Expires 2030-04-23 F2 · security: Stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| April 24, 2020 Filed Apr 28, 2020 21:25 UTC |
NOVAKOVIC PHEBE NDirector
|
GrantCommon shares without par value | 1,974 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-005186 · edgar.xml · nonDerivative · entry 1 NOVAKOVIC PHEBE N · CIK 0001222195 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,307 F1 · shares: These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| April 24, 2020 Filed Apr 28, 2020 21:26 UTC |
OSBORN WILLIAM ADirector
|
GrantOption (right to buy) · Derivative | 9,991 | $0.00 Strike: $93.68 | $0.00 |
DisclosureSEC source: 0001179110-20-005187 · edgar.xml · derivative · entry 2 OSBORN WILLIAM A · CIK 0001171797 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,991 Underlying: Common shares · 9,991 shares Expires 2030-04-23 F2 · security: Stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| April 24, 2020 Filed Apr 28, 2020 21:26 UTC |
OSBORN WILLIAM ADirector
|
GrantCommon shares without par value | 1,974 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-005187 · edgar.xml · nonDerivative · entry 1 OSBORN WILLIAM A · CIK 0001171797 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,297 F1 · shares: These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| April 24, 2020 Filed Apr 28, 2020 21:26 UTC |
STARKS DANIEL JDirector
|
GrantCommon shares without par value | 1,974 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-005188 · edgar.xml · nonDerivative · entry 1 STARKS DANIEL J · CIK 0000902132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,020,399 F1 · shares: These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| April 24, 2020 Filed Apr 28, 2020 21:27 UTC |
Stratton John GDirector
|
GrantCommon shares without par value | 1,974 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-005189 · edgar.xml · nonDerivative · entry 1 Stratton John G · CIK 0001385262 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,615 F1 · shares: These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| April 24, 2020 Filed Apr 28, 2020 21:27 UTC |
TILTON GLENN FDirector
|
GrantCommon shares without par value | 1,974 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-005190 · edgar.xml · nonDerivative · entry 1 TILTON GLENN F · CIK 0001194624 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,027 F1 · shares: These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| April 21, 2020 Filed Apr 24, 2020 01:26 UTC |
Contreras JaimeSenior Vice President
|
Exercise / conversionOption (right to buy) · Derivative | 25,681 | $0.00 Strike: $75.90 | $0.00 |
DisclosureSEC source: 0001179110-20-005067 · edgar.xml · derivative · entry 11 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,364 Underlying: Common shares · 25,681 shares Expires 2029-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| April 21, 2020 Filed Apr 24, 2020 01:26 UTC |
Contreras JaimeSenior Vice President
|
Exercise / conversionOption (right to buy) · Derivative | 36,715 | $0.00 Strike: $59.94 | $0.00 |
DisclosureSEC source: 0001179110-20-005067 · edgar.xml · derivative · entry 10 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,715 Underlying: Common shares · 36,715 shares Expires 2028-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| April 21, 2020 Filed Apr 24, 2020 01:26 UTC |
Contreras JaimeSenior Vice President
|
Exercise / conversionOption (right to buy) · Derivative | 46,016 | $0.00 Strike: $44.40 | $0.00 |
DisclosureSEC source: 0001179110-20-005067 · edgar.xml · derivative · entry 9 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 46,016 shares Expires 2027-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| April 21, 2020 Filed Apr 24, 2020 01:26 UTC |
Contreras JaimeSenior Vice President
|
Tax withholdingCommon shares without par value | 83,226 | $98.00 | $8,156,148.00 |
DisclosureSEC source: 0001179110-20-005067 · edgar.xml · nonDerivative · entry 4 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,205 Read SEC document |
| April 21, 2020 Filed Apr 24, 2020 01:26 UTC |
Contreras JaimeSenior Vice President
|
Exercise / conversionCommon shares without par value | 25,681 | $75.90 | $1,949,187.90 |
DisclosureSEC source: 0001179110-20-005067 · edgar.xml · nonDerivative · entry 3 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,431 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 21, 2020 Filed Apr 24, 2020 01:26 UTC |
Contreras JaimeSenior Vice President
|
Exercise / conversionCommon shares without par value | 36,715 | $59.94 | $2,200,697.10 |
DisclosureSEC source: 0001179110-20-005067 · edgar.xml · nonDerivative · entry 2 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 21, 2020 Filed Apr 24, 2020 01:26 UTC |
Contreras JaimeSenior Vice President
|
Exercise / conversionCommon shares without par value | 46,016 | $44.40 | $2,043,110.40 |
DisclosureSEC source: 0001179110-20-005067 · edgar.xml · nonDerivative · entry 1 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,035 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 21, 2020 Filed Apr 24, 2020 01:27 UTC |
Funck, Jr. Robert E.Executive Vice President & CFO
|
Exercise / conversionOption (right to buy) · Derivative | 13,000 | $0.00 Strike: $39.12 | $0.00 |
DisclosureSEC source: 0001179110-20-005068 · edgar.xml · derivative · entry 8 Funck Robert E · CIK 0001565892 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,325 Underlying: Common shares · 13,000 shares Expires 2024-02-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| April 21, 2020 Filed Apr 24, 2020 01:27 UTC |
Funck, Jr. Robert E.Executive Vice President & CFO
|
Exercise / conversionOption (right to buy) · Derivative | 23,700 | $0.00 Strike: $34.94 | $0.00 |
DisclosureSEC source: 0001179110-20-005068 · edgar.xml · derivative · entry 7 Funck Robert E · CIK 0001565892 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 23,700 shares Expires 2023-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| April 21, 2020 Filed Apr 24, 2020 01:27 UTC |
Funck, Jr. Robert E.Executive Vice President & CFO
|
Tax withholdingCommon shares without par value | 23,855 | $98.00 | $2,337,790.00 |
DisclosureSEC source: 0001179110-20-005068 · edgar.xml · nonDerivative · entry 3 Funck Robert E · CIK 0001565892 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,217 Read SEC document |
| April 21, 2020 Filed Apr 24, 2020 01:27 UTC |
Funck, Jr. Robert E.Executive Vice President & CFO
|
Exercise / conversionCommon shares without par value | 13,000 | $39.12 | $508,560.00 |
DisclosureSEC source: 0001179110-20-005068 · edgar.xml · nonDerivative · entry 2 Funck Robert E · CIK 0001565892 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 206,072 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 21, 2020 Filed Apr 24, 2020 01:27 UTC |
Funck, Jr. Robert E.Executive Vice President & CFO
|
Exercise / conversionCommon shares without par value | 23,700 | $34.94 | $828,078.00 |
DisclosureSEC source: 0001179110-20-005068 · edgar.xml · nonDerivative · entry 1 Funck Robert E · CIK 0001565892 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,072 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 21, 2020 Filed Apr 24, 2020 01:28 UTC |
Scoggins Christopher JSenior Vice President
|
SaleCommon shares without par value | 414 | $96.10 | $39,785.40 |
DisclosureSEC source: 0001179110-20-005069 · edgar.xml · nonDerivative · entry 1 Scoggins Christopher J · CIK 0001772286 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,706 Read SEC document |
| April 21, 2020 Filed Apr 24, 2020 01:34 UTC |
CAPEK JOHN MExecutive Vice President
|
Exercise / conversionOption (right to buy) · Derivative | 50,100 | $0.00 Strike: $22.39 | $0.00 |
DisclosureSEC source: 0001179110-20-005070 · edgar.xml · derivative · entry 4 CAPEK JOHN M · CIK 0001328034 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 50,100 shares Expires 2021-02-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| April 21, 2020 Filed Apr 24, 2020 01:34 UTC |
CAPEK JOHN MExecutive Vice President
|
SaleCommon shares without par value | 18,701 | $96.28 | $1,800,595.86 |
DisclosureSEC source: 0001179110-20-005070 · edgar.xml · nonDerivative · entry 3 CAPEK JOHN M · CIK 0001328034 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 316,800 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $96.14 to $96.52, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 21, 2020 Filed Apr 24, 2020 01:34 UTC |
CAPEK JOHN MExecutive Vice President
|
SaleCommon shares without par value | 31,399 | $95.63 | $3,002,730.33 |
DisclosureSEC source: 0001179110-20-005070 · edgar.xml · nonDerivative · entry 2 CAPEK JOHN M · CIK 0001328034 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 335,501 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $95.14 to $96.135, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 21, 2020 Filed Apr 24, 2020 01:34 UTC |
CAPEK JOHN MExecutive Vice President
|
Exercise / conversionCommon shares without par value | 50,100 | $22.39 | $1,121,834.19 |
DisclosureSEC source: 0001179110-20-005070 · edgar.xml · nonDerivative · entry 1 CAPEK JOHN M · CIK 0001328034 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 366,900 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 21, 2020 Filed Apr 24, 2020 01:41 UTC |
Ginascol John FExecutive Vice President
|
Exercise / conversionOption (right to buy) · Derivative | 63,200 | $0.00 Strike: $38.40 | $0.00 |
DisclosureSEC source: 0001179110-20-005071 · edgar.xml · derivative · entry 4 Ginascol John F · CIK 0001778075 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,133 Underlying: Common shares · 63,200 shares Expires 2026-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| April 21, 2020 Filed Apr 24, 2020 01:41 UTC |
Ginascol John FExecutive Vice President
|
SaleCommon shares without par value | 39,234 | $96.26 | $3,776,629.53 |
DisclosureSEC source: 0001179110-20-005071 · edgar.xml · nonDerivative · entry 3 Ginascol John F · CIK 0001778075 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,445 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $96.10 to $96.44, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 21, 2020 Filed Apr 24, 2020 01:41 UTC |
Ginascol John FExecutive Vice President
|
SaleCommon shares without par value | 23,966 | $95.57 | $2,290,421.03 |
DisclosureSEC source: 0001179110-20-005071 · edgar.xml · nonDerivative · entry 2 Ginascol John F · CIK 0001778075 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,679 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $95.10 to $96.095, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 21, 2020 Filed Apr 24, 2020 01:41 UTC |
Ginascol John FExecutive Vice President
|
Exercise / conversionCommon shares without par value | 63,200 | $38.40 | $2,426,880.00 |
DisclosureSEC source: 0001179110-20-005071 · edgar.xml · nonDerivative · entry 1 Ginascol John F · CIK 0001778075 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,645 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 22:25 UTC |
LANE ANDREW HExecutive Vice President
|
Tax withholdingCommon shares without par value | 365 | $78.91 | $28,802.15 |
DisclosureSEC source: 0001179110-20-004685 · edgar.xml · nonDerivative · entry 2 LANE ANDREW H · CIK 0001643735 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,822 Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 22:25 UTC |
LANE ANDREW HExecutive Vice President
|
GrantCommon shares without par value | 1,659 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-004685 · edgar.xml · nonDerivative · entry 1 LANE ANDREW H · CIK 0001643735 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,187 F1 · shares: Settlement of performance-based restricted stock units in shares in a transaction exempt from Section 16(b) under Rule 16b-3. F2 · balance_after: Includes shares acquired pursuant to a dividend reinvestment feature. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 22:25 UTC |
Scoggins Christopher JSenior Vice President
|
Tax withholdingCommon shares without par value | 1,048 | $78.91 | $82,697.68 |
DisclosureSEC source: 0001179110-20-004686 · edgar.xml · nonDerivative · entry 1 Scoggins Christopher J · CIK 0001772286 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,120 Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 22:26 UTC |
WOODGRIFT RANDEL WILLIAMSenior Vice President
|
Tax withholdingCommon shares without par value | 1,368 | $78.91 | $107,948.88 |
DisclosureSEC source: 0001179110-20-004687 · edgar.xml · nonDerivative · entry 1 WOODGRIFT RANDEL WILLIAM · CIK 0001204554 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,491 Read SEC document |
| March 31, 2020 Filed Apr 1, 2020 21:02 UTC |
Contreras JaimeSenior Vice President
|
Tax withholdingCommon shares without par value | 343 | $79.34 | $27,213.62 |
DisclosureSEC source: 0001179110-20-004340 · edgar.xml · nonDerivative · entry 5 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 2,624 F4 · balance_after: The reporting person disclaims beneficial ownership of all securities held by his spouse. Read SEC document |
| March 31, 2020 Filed Apr 1, 2020 21:02 UTC |
Contreras JaimeSenior Vice President
|
GrantCommon shares without par value | 740 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-004340 · edgar.xml · nonDerivative · entry 4 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 2,967 F3 · shares: This grant represents a restricted stock unit award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting on each anniversary of the grant date. The award includes the right to have stock withheld for tax purposes. F4 · balance_after: The reporting person disclaims beneficial ownership of all securities held by his spouse. Read SEC document |
| March 31, 2020 Filed Apr 2, 2020 21:49 UTC |
Alpern Robert JDirector
|
GrantStock Equivalent Units · Derivative | 99 | $78.91 | $7,812.09 |
DisclosureSEC source: 0001179110-20-004562 · edgar.xml · derivative · entry 1 Alpern Robert J · CIK 0001448074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,897 Underlying: Common Shares · 99 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock. F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock. F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| March 31, 2020 Filed Apr 2, 2020 21:50 UTC |
Stratton John GDirector
|
GrantStock Equivalent Units · Derivative | 399 | $78.91 | $31,485.09 |
DisclosureSEC source: 0001179110-20-004563 · edgar.xml · derivative · entry 1 Stratton John G · CIK 0001385262 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,069 Underlying: Common Shares · 399 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock. F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock. F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| March 13, 2020 Filed Mar 16, 2020 22:47 UTC |
Boudreau Philip PVice President
|
SaleCommon shares without par value | 10,600 | $82.00 | $869,200.00 |
DisclosureSEC source: 0001179110-20-003729 · edgar.xml · nonDerivative · entry 1 Boudreau Philip P · CIK 0001805099 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,463 Read SEC document |
| March 06, 2020 Filed Mar 10, 2020 21:06 UTC |
Watkin JaredSenior Vice President
|
SaleCommon shares without par value | 8,248 | $82.00 | $676,336.00 |
DisclosureSEC source: 0001179110-20-003412 · edgar.xml · nonDerivative · entry 1 Watkin Jared · CIK 0001645118 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,696 Read SEC document |
| March 02, 2020 Filed Mar 3, 2020 22:10 UTC |
Wainer Andrea FExecutive Vice President
|
SaleCommon shares without par value | 1,429 | $77.89 | $111,304.81 |
DisclosureSEC source: 0001179110-20-002891 · edgar.xml · nonDerivative · entry 2 Wainer Andrea F · CIK 0001778070 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,498 Read SEC document |
| March 02, 2020 Filed Mar 3, 2020 22:13 UTC |
BRYNELSEN CHARLESSenior Vice President
|
SaleCommon shares without par value | 1,781 | $77.89 | $138,722.09 |
DisclosureSEC source: 0001179110-20-002893 · edgar.xml · nonDerivative · entry 2 BRYNELSEN CHARLES · CIK 0001712459 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,460 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.